Hsbc Holdings PLC cut its stake in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 5.4% during the second quarter, Holdings Channel reports. The firm owned 645,767 shares of the medical instruments supplier’s stock after selling 36,591 shares during the quarter. Hsbc Holdings PLC’s holdings in Becton, Dickinson and Company were worth $97,770,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Brighton Jones LLC grew its holdings in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Becton, Dickinson and Company by 4.4% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,900 shares of the medical instruments supplier’s stock worth $122,403,000 after acquiring an additional 26,671 shares in the last quarter. Cooke & Bieler LP boosted its position in Becton, Dickinson and Company by 27.2% during the 4th quarter. Cooke & Bieler LP now owns 1,126,471 shares of the medical instruments supplier’s stock worth $218,614,000 after acquiring an additional 240,673 shares during the period. Northside Capital Management LLC grew its stake in Becton, Dickinson and Company by 18.3% during the 2nd quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock valued at $9,280,000 after acquiring an additional 9,494 shares in the last quarter. Finally, Wealthfront Advisers LLC purchased a new position in Becton, Dickinson and Company during the 2nd quarter valued at about $2,567,000. 86.97% of the stock is owned by hedge funds and other institutional investors.
Becton, Dickinson and Company Stock Performance
Shares of BDX opened at $190.22 on Thursday. The company has a market capitalization of $52.41 billion, a PE ratio of 57.30, a price-to-earnings-growth ratio of 13.38 and a beta of 0.19. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $193.07. The company’s fifty day moving average price is $164.35 and its 200 day moving average price is $160.49.
Becton, Dickinson and Company Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 126.51%.
Insider Activity
In other news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. This represents a 3.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. This trade represents a 7.71% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 11,704 shares of company stock worth $1,963,618. Company insiders own 0.40% of the company’s stock.
Analysts Set New Price Targets
BDX has been the subject of a number of research analyst reports. Jefferies Financial Group reissued a “buy” rating and issued a $210.00 price target on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Bank of America dropped their price objective on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. Barclays increased their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. UBS Group began coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price for the company. Finally, The Goldman Sachs Group lowered their price target on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 27th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $185.67.
Get Our Latest Stock Report on Becton, Dickinson and Company
About Becton, Dickinson and Company
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Read More
- Five stocks we like better than Becton, Dickinson and Company
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
